Anti-TIF1-γ antibody and cancer-associated myositis

Neurology

Volumn 87, Issue 3, 2016, Pages 299-308

  Hida, Ayumi ^a   Yamashita, Takenari ^a   Hosono, Yuji ^b   Inoue, Manami ^a   Kaida, Kenichi ^c   Kadoya, Masato ^c   Miwa, Yusuke ^d   Yajima, Nobuyuki ^d   Maezawa, Reika ^e   Arai, Satoko ^e   Kurasawa, Kazuhiro ^e   Ito, Kazuhiro ^f   Shimada, Hiroyuki ^f   Iwanami, Tomoko ^g   Sonoo, Masahiro ^g   Hatanaka, Yuki ^g,h   Murayama, Shigeo ⁱ   Uchibori, Ayumi ⁱ   Chiba, Atsuro ⁱ   Aizawa, Hitoshi ^j,k   Momoo, Takayuki ^l   Nakae, Yoshiharu ^l   Sakurai, Yasuhisa ^m   Shiio, Yasushi ⁿ   Hashida, Hideji ^o   Yoshizawa, Toshihiro ^p   Sakiyama, Yoshio ^q   Oda, Aya ^q   Inoue, Kiyoharu ^r   Takeuchi, Sousuke ^s   Iwata, Nobue K ^t   Date, Hidetoshi ^a   Masuda, Naoki ^u   Mikata, Takashi ^v   Motoyoshi, Yasufumi ^v   Uesaka, Yoshikazu ^w   Maeda, Meiko Hashimoto ^w   Nakashima, Ran ^a   Tsuji, Shoji ^a   Kwak, Shin ^a   Mimori, Tsuneyo ^a   Shimizu, Jun ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TEIKYO UNIVERSITY   (Japan)

^h Itabashi Chuo Medical Center   (Japan)

ⁱ KYORIN UNIVERSITY   (Japan)

^j TOKYO NATIONAL HOSPITAL   (Japan)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l Hiratsuka Kyosai Hospital   (Japan)

^m MITSUI MEMORIAL HOSPITAL   (Japan)

ⁿ TOKYO TEISHIN HOSPITAL   (Japan)

^o JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^p Kanto Teishin Hospital   (Japan)

^q JICHI MEDICAL UNIVERSITY   (Japan)

^r Sapporo Yamanoue Hospital   (Japan)

^s NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^t International University of Health and Welfare Mita Hospital   (Japan)

^u TOKYO KYOSAI HOSPITAL   (Japan)

^v NATIONAL HOSPITAL ORGANIZATION   (Japan)

^w TORANOMON HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C5B; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA ANTIBODY; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; NUCLEAR PROTEIN; TIAF1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER ASSOCIATED MYOSITIS; CELL VACUOLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMATITIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; MYOSITIS; NECROTIZING AUTOIMMUNE MYOPATHY; NEOPLASM; PRIORITY JOURNAL; BLOOD; COMPLICATION; IMMUNOLOGY; NEOPLASMS; RETROSPECTIVE STUDY;

APOPTOSIS REGULATORY PROTEINS; AUTOANTIBODIES; BIOMARKERS; FEMALE; HUMANS; MALE; MYOSITIS; NEOPLASMS; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES;

EID: 84979276169     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002863     Document Type: Article

References (36)

1. Dankó K, Ponyi A, Molnar AP, András C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol 2009; 21: 594-598
2. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-215
3. Vosskämper M, Korf B, Franke F, Schachenmayr W. Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis. J Neurol 1989; 236: 489-490
4. Urich H, Wilkinson M. Necrosis of muscle with carcinoma: myositis or myopathy? J Neurol Neurosurg Psychiatry 1970; 33: 398-407
5. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41: 936-939
6. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-3689
7. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007; 46: 25-28
8. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O?Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-Associated dermatomyositis: a systematic review and meta-Analysis. Arthritis Rheum 2012; 64: 523-532
9. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 2011; 43: 85-96
10. Vincent DF, Yan KP, Treilleux I, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 2009; 5: e1000575
11. Ding ZY, Jin GN, Wang W, et al. Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology 2014; 60: 1620-1636
12. Ligr M, Wu X, Daniels G, et al. Imbalanced expression of Tif1g inhibits pancreatic ductal epithelial cell growth. Am J Cancer Res 2014; 4: 196-210
13. Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum 2012; 64: 346-349
14. Benveniste O, Hilton-Jones D. International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 2009. Neuromuscul Disord 2010; 20: 414-421
15. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 2003, Naarden, the Netherlands. Neuromuscul Disord 2004; 14: 337-345
16. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-Associated myositis. Ann Rheum Dis 2007; 66: 1345-1349
17. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005; 84: 231-249
18. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010; 49: 1726-1733
19. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-Associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-721
20. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011; 23: 595-604
21. Dubowitz V, ed. Muscle Biopsy: A Practical Approach, 4th ed. Philadelphia: Saunders
22. Carpenter S, Karpati G, Rothman S, Watters G. The childhood type of dermatomyositis. Neurology 1976; 26: 952-962
23. Karpati G. Disorders of Voluntary Muscle, 8th ed. New York: Cambridge University Press 2010
24. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347
25. Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011; 21: 178-183
26. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100
27. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-367
28. Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol 2009; 161: 854-860
29. Kuo CF, See LC, Yu KH, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011; 165: 1273-1279
30. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12: R70
31. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015; 52: 196-203
32. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008; 47: 324-328
33. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513-522
34. Fernandez C, Bardin N, De Paula AM, et al. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine 2013; 92: 15-24
35. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361-1370
36. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7: 343-354